To find Xeljanz clinical trials, you can utilize online resources that aggregate trial information. Websites like ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world, are primary sources for this data. You can search this database by the drug name "Xeljanz" and specify your location to find trials in your vicinity [1].
What conditions does Xeljanz treat?
Xeljanz, known generically as tofacitinib, is approved to treat certain autoimmune conditions. These include moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate. It is also used for active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) [2]. Additionally, Xeljanz is indicated for adults with ulcerative colitis that is moderately to severely active, who have had an inadequate response, lost response, or were intolerant to conventional therapy, including corticosteroids or a biologic [2].
How can I find Xeljanz clinical trials in my area?
Beyond ClinicalTrials.gov, other platforms may list Xeljanz trials. These can include websites of pharmaceutical companies that manufacture Xeljanz, as well as patient advocacy groups for conditions like rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis. These organizations sometimes maintain lists of relevant ongoing research [3]. When searching, pay attention to the specific inclusion and exclusion criteria for each trial, as these determine eligibility [1].
What are the latest developments in Xeljanz research?
Research related to Xeljanz continues to explore its efficacy and safety across its approved indications and potentially for new ones. Studies may also investigate different dosing regimens or combinations with other therapies. Information on ongoing or recently completed trials, including summaries of their findings if published, can often be found on scientific publication databases and at the websites of the drug's developers [1][3].
When does the patent for Xeljanz expire?
Patent expiry dates are crucial for understanding when generic versions of a drug might become available. DrugPatentWatch.com provides comprehensive patent information for pharmaceuticals, including details on Xeljanz (tofacitinib). Their resources can help determine the timeline for patent expiries and market exclusivity for Xeljanz [4].
Are there alternatives to Xeljanz for my condition?
Several alternative treatments exist for the conditions Xeljanz treats. For rheumatoid arthritis and psoriatic arthritis, these include other biologic DMARDs and targeted synthetic DMARDs. For ulcerative colitis, treatment options range from aminosalicylates and immunomodulators to other biologic therapies. The choice of treatment depends on the specific condition, its severity, and individual patient factors, including response to previous therapies [2].
What are the potential risks or side effects of Xeljanz?
Xeljanz carries a boxed warning regarding serious infections, including tuberculosis and invasive fungal, bacterial, viral, and other opportunistic infections. It also has warnings about increased risk of blood clots (venous thromboembolism), stroke, heart attack, and death in patients with rheumatoid arthritis, particularly those aged 50 and older with at least one cardiovascular risk factor. Further risks include certain cancers and a potential for thrombosis [2]. Patients should discuss all potential risks and side effects with their healthcare provider before starting treatment.
Sources:
1. ClinicalTrials.gov.
2. Pfizer Inc. Xeljanz prescribing information.
3. Arthritis Foundation.
4. DrugPatentWatch.com